Prostate Cancer
Conditions
Interventions
Control group:None
Observation group:None
Sponsors
Aerospace Center Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. According to the Prostate Cancer Diagnosis and Treatment Guidelines (2022 Edition), patients diagnosed with prostate cancer, 2. Aged between 18-100 years old, 3. Patients with histologically confirmed suitability for endocrine therapy (excluding neoadjuvant endocrine therapy) or local therapy who have received = 1.5 ng/mL, 5. Expected survival period >9 months, 6. Eastern Cooperative Oncology Group (ECOG) performance status score <=2, 7. Treatment with goserelin microspheres or goserelin implants 3.6mg q28d, 8. Voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with prostate cancer who have previously or are currently receiving hormone therapy 2. Diagnosis or suspected of having hormone-resistant prostate cancer 3. Pituitary resection, adrenalectomy, or pituitary lesions, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with serum testosterone =20ng/dl on day 29 after the first administration of medication.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The cumulative probability of maintaining serum testosterone =50ng/dl from day 29 to day 169;Percentage of patients with serum testosterone =50ng/dl on day 29 after the first administration of medication;The cumulative probability of maintaining serum testosterone =20ng/dl from day 29 to day 169;Assess the incidence of injection site adverse reactions such as pain and bleeding at the patient's injection site at 1, 3, and 6 months after medication administration.; | — |
Countries
China
Contacts
Public ContactLi Chunxing, Liu Hua
Aerospace Center Hospital
Outcome results
None listed